Replies to post #137740 on Biotech Values

[Summer2762]

The MTD for TH-302 is 575 mg/m2.

That's for monotherapy. With gemcitabine the MTD was established to be 340 mg/m2.

In general, be mindful of PFS data in an open label study (especially if the study allows crossover). I would wait to see a) LA/M ratio to validate 3.6m median for gem arm b) dropout ratios in both arms.